Source: Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016



Rating:

Share or cite this content

Citations should be made in the following way:
Samuel T. Montgomery, Marcus A. Mall, Anthony Kicic, Stephen M. Stick, on behalf of AREST CF. Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies. Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms and markers of airway inflammation in cystic fibrosis Source: Eur Respir J 2002; 19: 333-340 Year: 2002 New insights into the pathophysiology of lung disease in cystic fibrosis patients Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1 Year: 2006 Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages Source: Eur Respir J, 57 (6) 2003502; 10.1183/13993003.03502-2020 Year: 2021 The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects Source: Eur Respir Rev, 30 (161) 210055; 10.1183/16000617.0055-2021 Year: 2021 Lack of an exaggerated inflammatory response on virus infection in cystic fibrosis Source: Eur Respir J 2012; 39: 297-304 Year: 2012 Inflammatory cytokines in airway secretions from patients with cystic fibrosis contribute to airway epithelial cell damage Source: Eur Respir J 2004; 24: Suppl. 48, 384s Year: 2004 Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 Characterization of cystic fibrosis airway epithelium in vitro Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019 Year: 2020 The role of chemokines and cytokines in lung fibrosis Source: Eur Respir Rev 2008; 17: 151-156 Year: 2008 Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms Source: Eur Respir J 2008; 31: 396-406 Year: 2008 Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Airway inflammation in cystic fibrosis Source: Eur Respir Monogr 2014; 64: 14-31 Year: 2014 Current concepts: host–pathogen interactions in cystic fibrosis airways disease Source: Eur Respir Rev 2014; 23: 320-332 Year: 2014 Role of neutrophil mechanisms of inflammation in pathogenesis of different types of pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003 Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005